Intercept Pharmaceuticals | ICPT - Ebitda


Intercept Pharmaceuticals reported $-7.03M in EBITDA for its fiscal quarter ending in June of 2023.



Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.8B 1.25B Sep/2026
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Galectin Therapeutics USD -7.42M 819K Dec/2021
Gilead Sciences USD -9.31B 12.82B Jun/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -95.22M 9.99M Sep/2026
Moderna USD -687M 571M Jun/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Novartis USD 8.62B 2.14B Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026